ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

COO Buys $4M in Uber; Cybin Directors Pile In

By ORTEX News · Edited by , Editor, ORTEX News1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Two US-listed companies saw notable open-market insider buying filed on September 8, with executives putting their own money on the line.

UBER President and COO Andrew Gordon MacDonald filed purchases totalling roughly $5.3 million in Uber stock. The trades were executed on September 4 at around $75.65 per share. A sitting COO writing an eight-figure personal cheque — across two separate purchases on the same day — is a clear show of confidence. Uber's market cap sits at around $145 billion, with short interest a modest 2.1% of free float.

On the same filing date, two directors at psychedelic biotech HELP (Cybin Inc.) disclosed combined purchases of roughly $2.4 million. Eric So bought $1.2 million worth, while Paul Glavine added $1.18 million. Both traded on September 3–4. Back-to-back director buying at a sub-$1 billion biotech is a strong signal. Cybin has short interest of 5.1% of free float.

Globally, ROBOTIS CEO Kim Byeong Soo filed a $75 million sale of his own company's South Korean-listed shares. That is among the largest C-level disposals reported on the date, though such a large founder sale often reflects diversification rather than a negative view on the business.

Private equity firm L Catterton also filed a $94 million exit from Italian cosmetics firm Intercos — a typical PE liquidity event.

This article is for informational purposes only and does not constitute financial advice.

Stocks in this article

How this article was generated

Generated
23 Sept 2026, 08:32
Prompt version
v1.0
Data sources
Institutional positioning

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.